Jeani Delagardelle
Jeani Delagardelle is a managing director of New Leaf Venture Partners, a healthcare technology fund established in August 2005 by the healthcare technology partners of the Sprout Group. Ms. Delagardelle joined Sprout in August 2000 and became General Partner in July 2001. Previously, she was a general partner focused on healthcare investments at Weiss, Peck & Greer Venture Partners. Before joining Weiss, Peck & Greer, Ms. Delagardelle spent 15 years in senior marketing, sales, business development and general manager positions in the healthcare industry. During this time she served as vice president of Global Marketing for Target Therapeutics (acquired by Boston Scientific for $1.1 billion) and held several senior management roles in the Medi-tech division of Boston Scientific. Ms. Delagardelle also served as director of Business Operations for Roche Laboratories and director of Global Marketing for Cell Pro, Inc.

In addition to her work with Spiracur she also serves on the Board of Directors of Access Closure Inc., Direct Flow Medical, Intrinsic Therapeutics, ReShape Medical, Spiration and World Heart.

Ms. Delagardelle holds an MBA from the University of California at Irvine and an A.B. from Occidental College.

Chris Fashek
Chris is the Executive Chairman of Systagenix Wound Management.  Systagenix Wound Management represents key wound care brands including Regranex®, SilverCel™, Promogran™ and Prisma™. Previously, Mr. Fashek served as president and Vice Chairman of Kinetic Concepts, Inc (KCI) USA, which is a $1.0 Billion plus business in the wound care category. Prior to that, Chris managed businesses in the pharmaceutical and consumer product markets.  Chris currently serves as an advisory board member of IDN Summit, Vice Chairman of the World Craniofacial Foundation, and other commercial and charitable boards. Chris has an MBA from Fairleigh Dickinson University, New Jersey and a BA from Upsala College, New Jersey.

Rich Ferrari
Rich has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo Ventures in 2000. Following De Novo’s investment in CryoVascular Systems, Rich became CEO, growing the initial 5 person start up team to a company of 20 employees. He was instrumental in developing the clinical and product strategies and hiring the executive team. In 2002, Rich led Paracor Medical, another De Novo portfolio company. He grew the company from 4 to 22 employees, refined the product strategy, raised its Series B financing and hired his replacement CEO. Prior to co-founding De Novo Ventures, he was the co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was ultimately acquired by Guidant Corporation in November 1999. Before that, Rich was the CEO of Cardiovascular Imaging Systems (“CVIS”). As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific Corporation in 1995.
 
In addition, Rich founded Saratoga Ventures in 1996, a venture capital partnership that has provided seed financing to startup medical technology companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. At Saratoga, Rich was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, an early stage femoral artery closure company which was sold to Abbott and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Rich held the position of Executive Vice President and General Manager of ADAC Laboratories. Rich holds a BS degree from Ashland University and an MBA from the University of South Florida.
 
In addition to Spiracur, Rich sits on the boards of BenVenue, CardioMind, MyoScience, Ovalis, Paracor Medical, Pulmonx, Simpirica, Spinal Kinetics and Spinal Modulation.  His prior board involvement includes TriVascular.

Dana Mead
Dana joined Kleiner Perkins Caufield & Byers as a partner in May 2005 to work in the life sciences practice.

For the past 23 years, Dana's career has focused on identifying new medical technologies, developing new markets and therapies, and building world-class management teams. He has worked with physician thought leaders around the world representing 10 different medical specialties. At KPCB, Dana leverages experience gained from his venture-funded, start-up management roles and board participation to support entrepreneurs and innovators dedicated to making a real difference in the lives of millions suffering from life-limiting disease.

Prior to joining KPCB, Dana was President of Guidant Vascular Intervention, a fully integrated billion dollar division with over 4,500 employees. After joining Guidant in 1992, he held positions of increasing responsibility including: Vice President and General Manager, Cardiac & Vascular Surgery; Vice President and General Manager, Stents, Vascular Intervention Group; President, Japan and A/P Operations based in Tokyo; and Vice President, Corporate Relations and Policy with responsibility for investor relations, corporate communications, corporate marketing and public policy initiatives. Prior to joining Guidant, Dana worked in various sales and marketing roles at Allergan, Inc. and Johnson & Johnson. A native of Connecticut, Dana received his Bachelor's degree from Lafayette College and holds an MBA degree from the University of Southern California. Dana serves on the boards of AesThera, Inc., Corventis, Navigenics, Inc., OtisMed Corporation, Sinexus, Inc., Synvascular, Invuity, Inc., Spinal Modulation, Inspire Medical Systems, Voyage Medical, the California Healthcare Institute (CHI), the Cardiovascular Research Foundation (CRF), and Lucile Packard Children’s Hospital.